Myeloproliferative Neoplasms (MPN)

Dr. O’Connell is an academic hematologist with the Jane Anne Nohl Division of Hematology at the Keck School of Medicine of University of Southern California (USC). In addition to her clinical work with patients at the Norris Comprehensive Cancer Center, she conducts clinical and translational research in Myeloproliferative and Myelodysplastic Syndromes (MDS). She is currently the principal investigator at USC on various clinical trials, the most exciting of which is a Phase I trial utilizing a novel hypomethylating agent for patients with MDS and acute myeloid leukemia. This trial is supported

Dr. Pollyea received his MD degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency in Internal Medicine and served as Chief Medical Resident at Cook County Hospital. He then completed his fellowship training in Hematology and Oncology at Stanford University, where he also completed a Masters degree in Epidemiology with an emphasis on biostatistics and clinical trial design. In 2011 he came to the University of Colorado where he is currently the Clinical Director of Leukemia Services. Dr. Pollyea has served as the

As a blood cancer specialist and also a palliative care physician, Dr. LeBlanc bring a different focus to cancer care. He is working hard to improve the treatment experience for patients who are living with blood cancers. By understanding your experience better, Dr. LeBlanc believes we can develop new ways to improve your quality of life, and provide additional support throughout your treatment and beyond.

Ruben A. Mesa, MD, FACP, is the president and executive director of Atrium Health Levine Cancer and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He also serves as vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. In his roles, Dr. Mesa oversees all efforts related to cancer practice, research and education across the Atrium Health system. Dr. Mesa is an international expert in hematologic cancers. He has dedicated his life's work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based

After obtaining a BA/MS as a Vagelos Scholar in Molecular Life Sciences at the University of Pennsylvania in 2003, Dr. Lee received his MD from the University of Miami in 2007. Following his internal medicine residency at the University of Alabama at Birmingham, he completed his fellowship in hematology and oncology at the New York Presbyterian Hospital/Columbia University Medical Center from 2010-2013 where he focused on epigenetics of myelodysplastic syndromes (MDS) under Drs. Azra Raza and Benjamin Tycko. In July 2013, Dr. Lee was recruited to serve in the Leukemia Program in the Division

Dr. Lane received his MD and PhD degrees from Washington University. He completed his residency in internal medicine at Brigham and Women's Hospital, and his fellowships in hematology and medical oncology at DFCI. His research focuses on developing new treatments for leukemia by studying the genetic changes that occur in cancer and how they alter the normal development of blood cells.